Is the OnKure Therapeutics (OKUR) CFO’s share sale considered an open-market transaction?

The transaction code indicates a sale, and the filing notes trades occurred between $3.995 and $4.235 . However, a footnote clarifies these shares were automatically sold specifically to satisfy RSU-related tax withholding obligations rather than a discretionary market-timing decision.

OnKure Therapeutics (OKUR) CFO sells 301 shares to cover RSU tax withholding

Q: Why did the OnKure Therapeutics (OKUR) CFO sell 301 shares in this Form 4?

The 301 shares were sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units under OnKure’s 2023 RSU Equity Incentive Plan , making this a tax-related transaction rather than a discretionary open-market sale.

Q: What price did the OnKure Therapeutics (OKUR) CFO receive for the shares sold?

The reported weighted average sale price was $4.1565 per share. The transaction was executed in multiple trades at prices ranging from $3.995 to $4.235 , with the weighted average used as the disclosed transaction price.

Q: Were derivatives or options involved in this OnKure Therapeutics (OKUR) Form 4 filing?

The filing describes the sale as related to vesting restricted stock units (RSUs) , where each RSU represents a right to receive one share of Class A Common Stock. The derivative summary in the provided data shows no separate derivative transactions reported in this specific filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. Chief Financial Officer Jason A. Leverone reported an automatic sale of 301 shares of Class A Common Stock. The shares were sold on March 23, 2026 at a weighted average price of $4.1565 per share.

According to the disclosure, the shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units under OnKure’s 2023 RSU Equity Incentive Plan, rather than as a discretionary trade. Following this tax-related sale, Leverone directly holds 16,000 shares of Class A Common Stock.

Insider Trade Summary

Net Seller: 301 shares ($1,251)

Net Sell 1 txn

Insider Leverone Jason A.

Role Chief Financial Officer

Sold 301 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	301	$4.1565	$1K

Holdings After Transaction: Class A Common Stock — 16,000 shares (Direct)

Footnotes (1)

These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/24/2026 - 06:56 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leverone Jason A.

(Last)

(First)

(Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER

COLORADO

80301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	03/23/2026		S⁽¹⁾		301	D	$4.1565⁽²⁾	16,000⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

2. This transaction was executed in multiple trades at prices ranging from $3.995 to $4.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

	/s/ Rogan Nunn, by power of attorney	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did OnKure Therapeutics (OKUR) report for its CFO?

OnKure Therapeutics reported that CFO Jason A. Leverone sold 301 shares of Class A Common Stock at a weighted average price of $4.1565 per share on March 23, 2026, in an automatic transaction linked to RSU vesting tax obligations.

Why did the OnKure Therapeutics (OKUR) CFO sell 301 shares in this Form 4?

The 301 shares were sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units under OnKure’s 2023 RSU Equity Incentive Plan, making this a tax-related transaction rather than a discretionary open-market sale.

What price did the OnKure Therapeutics (OKUR) CFO receive for the shares sold?

The reported weighted average sale price was $4.1565 per share. The transaction was executed in multiple trades at prices ranging from $3.995 to $4.235, with the weighted average used as the disclosed transaction price.

How many OnKure Therapeutics (OKUR) shares does the CFO hold after this transaction?

After the tax-related sale, CFO Jason A. Leverone directly holds 16,000 shares of OnKure Therapeutics Class A Common Stock, as reported in the Form 4, reflecting his remaining direct ownership position following the 301-share disposition.

Were derivatives or options involved in this OnKure Therapeutics (OKUR) Form 4 filing?

The filing describes the sale as related to vesting restricted stock units (RSUs), where each RSU represents a right to receive one share of Class A Common Stock. The derivative summary in the provided data shows no separate derivative transactions reported in this specific filing.